Class 4 Medicines Defect Information: BUCCOLAM (midazolam) Oromucosal Solution Pre-filled Syringes
- The problem
- Caution in Use: Distribute to Pharmacy, Hospital, GP, Dental Practice, Ward and Clinic Level.
- What to do
- Check the batch number on your pack against the list below. Do not stop taking a prescribed medicine without talking to your pharmacist, GP or prescriber first – they can check your supply and swap it if needed.
Product information
MDR number
MDR 134-10/17
Company name
Shire
Product description
BUCCOLAM (midazolam) 2.5 mg, 5 mg, 7.5 mg and 10 mg Oromucosal Solution Pre-filled Syringes
Marketing Authorisation number
- EU/1/11/709/001
- EU/1/11/709/002
- EU/1/11/709/003
- EU/1/11/709/004
Brief description of the problem
Shire has distributed the Direct Healthcare Professional Communication (DHCP) attached due to reports that the translucent tip-cap sometimes remains on the syringe tip when pulling the red cap off, as shown in the DHCP diagrams.
If this occurs, the translucent tip cap needs to be removed manually to enable administration of BUCCOLAM and to prevent it falling into the patient’s mouth upon application of extreme pressure. There have not yet been any reports of the translucent tip-cap falling into a patient’s mouth but this cannot theoretically be excluded.
This issue is applicable to all unexpired batches of BUCCOLAM currently in the marketplace.
Actions for healthcare professionals
As outlined in the DHCP attached, we ask you share this information with your patients’ parents and caregivers, and with age-appropriate patients, during your interactions with them going forward to ensure they are aware of this issue when handling the product.
Company contact information
Should you have any questions or require additional information on the use of BUCCOLAM
2.5 mg, 5 mg, 7.5 mg and 10 mg oromucosal solution, please contact:
Medical Information
Tel: 0800 055 6614
Email: MedinfoEMEA@shire.com
Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. NHS regional teams are asked to forward this to relevant clinics, hospital pharmacists, general practitioners, dental practices, dentists, nurses, neurologists, neurology specialist nurses, epilepsy specialist nurses and community pharmacists for information.
The DHCP letter has been circulated to a number of patient support groups.
Download document
Class 4 Drug Alert – Buccolam (midazolam) Buccal Solution – MDR 134-10/17
Updated 7 December 2017. This page summarises an official notice. Details can change – always follow the official notice.